Skip to main content


FibroACT is a noninvasive alternative to liver biopsy recommended by the American Association for the Study of Liver Diseases (AASLD), World Health Organization (WHO), Asia-Pacific Association for the Study of the Liver (APASL) and the European Association for the Study of the Liver (EASL) for non-invasive evaluation of hepatic fibrosis in chronic hepatitis C patients.  The test utilizes five serum biochemical markers, alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma-glutamyl transferase, and alanine aminotransferase, matched with the patient's age and gender to algorithmically generate a measurement of fibrosis and necroinflammatory activity in the liver. FibroACT is validated to differentiate hepatic cirrhosis from non-cirrhosis in individuals with HCV or other chronic liver diseases. Results are provided with an enhanced graphical report including a color-coded scale for fibrosis and inflammatory scores.

Hepatitis C Facts:

  • Affects an estimated 3.5 million people in the US who have Hepatitis C
  • The leading cause of liver cancer in the United States. 
  • 75 to 85 percent of HCV  infections become chronic conditions.  

Benefits of FibroACT:

  • Can assess injury to the liver following a diagnosis of HCV infection
  • Reduces the need for biopsy
  • Can be used for monitoring, frequently and safely
  • Non-invasive and no fasting required
  FibroACT Liver Biopsy
Contradiction Gilbert's syndrome and non-hepatic inflammation Uncooperative patient, severe coagulopathy, extrahepatic biliary obstruction, ascites, morbid obesity
Risks Very little to none Pain, bleeding, pneumothorax, hemothorax, infection
Cost Less expensive than biopsy Expensive
Limitation Indirect measurement of changes in the liver Sampling error, inter-observer variability, possible hospitalization
Test Nature Non-Invasive Invasive
Advantages Measurement of global fibrosis, suitable for monitoring Direct, evaluation of co-existing pathologies